RESEARCH. CURE. APPENDIX CANCER. Rare Disease Day | February 28, 2021  Appendix cancer is a rare disease often misdiagnosed, misunderstood, and under-researched.  Most patients diagnosed with appendix cancer may have even heard the words (including sometimes even by a physician) “well, at least it's nothing serious, it’s just your appendix.” False. Appendix cancer can be life-threatening and we must all...

ACPMP is pleased to present our revised and expanded list of clinical trials for appendix cancer/PMP patients. This list now includes "tumor agnostic" and "unspecified solid tumor" trials that may be appropriate for appendix cancer/PMP patients. Click here to visit our Clinical Trials page. ACPMP is committed to increasing participation in clinical trials among those living with appendix cancer and...

"Often uncovered by accident, appendiceal cancers trigger few symptoms until they’re advanced and can be difficult to detect and treat."  Dara Chadwick's article titled "Appendix Cancer: An Elusive Diagnosis" was released yesterday August 26, 2020. The article dives into the peculiarity of an appendix cancer diagnosis and features first hand commentary from our very own ACPMP President, Jerry Lewandowski, a...

ACPMP is pleased to announce the RFP is NOW OPEN for our 2020 Grant Cycle. ACPMP will offer two $50,000, 2-year grants for 2020. The 2020 grant timeline is as follows: RFP available: June 22, 2020 Abstract deadline: August 25, 2020 Full proposal invitations: Fall 2020 Full proposal deadline: Fall 2020 Award announcements: December 2020 ACPMP is the leading organization funding promising research worldwide...

FDA has now approved KEYTRUDA (pembrolizumab) for a second indication based on a tumor biomarker rather than the originating source of the tumor in the body.  Specifically, FDA has approved KEYTRUDA for patients with an unresectable or metastatic solid tumor with a high mutational burden (i.e, 10 or more mutations).  As part of this approval, FDA has also approved Foundation...

The ACPMP Research Foundation is excited to share that we are now a research partner of the Wake Forest Organoid Research Center (WFORCE). WFORCE is a joint effort between the Wake Forest Institute for Regenerative Medicine and the Wake Forest Comprehensive Cancer Center and brings together researchers and clinicians, working side by side, to leverage the use of tissue organoid technology for the benefit of...

The Appendix Cancer Pseudomyxoma Peritonei (ACPMP) Research Foundation is pleased to announce the recipients of our 2019 research grant cycle. Thank you as always to our dedicated fundraisers and to the many researchers who applied to our research grant program, and to our supporters—you are our inspiration. With these two grants, ACPMP has now issued $1,300,000 in the form of...

The ACPMP Research Foundation continues to follow with great interest the clinical research being conducted to identify appendiceal tumor characteristics against which novel drugs can be targeted to reduce, if not eliminate, disease.  We were pleased, therefore, with the recent addition to our website’s list of clinical trials of a currently recruiting Phase 1 clinical study of patients with solid...

The Appendix Cancer / Pseudomyxoma Peritonei Research Foundation (ACPMP) is pleased to announce the recipients of our 2018 research grant cycle. With these two grants, ACPMP has now issued $1,200,000 in the form of 25 promising research grants over the past 10 years designed to improve the diagnosis and treatment of Appendix Cancer and Pseudomyxoma Peritonei. These grants are issued...

The Appendix Cancer / Pseudomyxoma Peritonei Research Foundation (ACPMP) sponsored and participated in the 14th Annual International Symposium on Regional Cancer Therapies, presented by the Society of Surgical Oncology, which took place from February 16-18, 2019 at the Arizona Grand Resort in Phoenix, AZ. ACPMP expanded our investment in this exciting event by providing funding for three travel scholarships enabling young physicians...